188 related articles for article (PubMed ID: 19288144)
1. Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound.
Casini A; Gabbiani C; Michelucci E; Pieraccini G; Moneti G; Dyson PJ; Messori L
J Biol Inorg Chem; 2009 Jun; 14(5):761-70. PubMed ID: 19288144
[TBL] [Abstract][Full Text] [Related]
2. Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry.
Groessl M; Tsybin YO; Hartinger CG; Keppler BK; Dyson PJ
J Biol Inorg Chem; 2010 Jun; 15(5):677-88. PubMed ID: 20213306
[TBL] [Abstract][Full Text] [Related]
3. Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay.
Artner C; Holtkamp HU; Hartinger CG; Meier-Menches SM
J Inorg Biochem; 2017 Dec; 177():322-327. PubMed ID: 28739166
[TBL] [Abstract][Full Text] [Related]
4. Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action.
Casini A; Karotki A; Gabbiani C; Rugi F; Vašák M; Messori L; Dyson PJ
Metallomics; 2009 Sep; 1(5):434-41. PubMed ID: 21305148
[TBL] [Abstract][Full Text] [Related]
5. Trans-cis-cis-[RuCl2(DMSO)2(2-amino-5-methyl-thiazole)2], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B.
Mura P; Camalli M; Casini A; Gabbiani C; Messori L
J Inorg Biochem; 2010 Feb; 104(2):111-7. PubMed ID: 19939460
[TBL] [Abstract][Full Text] [Related]
6. Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: new insights from X-ray diffraction and mass spectrometry studies.
Casini A; Guerri A; Gabbiani C; Messori L
J Inorg Biochem; 2008; 102(5-6):995-1006. PubMed ID: 18289690
[TBL] [Abstract][Full Text] [Related]
7. Probing the interaction of cisplatin with cytochrome C by electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry.
Zhang N; Du Y; Cui M; Xing J; Liu Z; Liu S
Anal Chem; 2012 Jul; 84(14):6206-12. PubMed ID: 22746312
[TBL] [Abstract][Full Text] [Related]
8. Interactions of cisplatin and transplatin with proteins. Comparison of binding kinetics, binding sites and reactivity of the Pt-protein adducts of cisplatin and transplatin towards biological nucleophiles.
Peleg-Shulman T; Najajreh Y; Gibson D
J Inorg Biochem; 2002 Jul; 91(1):306-11. PubMed ID: 12121789
[TBL] [Abstract][Full Text] [Related]
9. A mass spectrometric comparison of the interactions of cisplatin and transplatin with myoglobin.
Zhao T; King FL
J Inorg Biochem; 2010 Feb; 104(2):186-92. PubMed ID: 19945168
[TBL] [Abstract][Full Text] [Related]
10. ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme.
Casini A; Mastrobuoni G; Temperini C; Gabbiani C; Francese S; Moneti G; Supuran CT; Scozzafava A; Messori L
Chem Commun (Camb); 2007 Jan; (2):156-8. PubMed ID: 17180231
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the binding of metal complexes to duplex and quadruplex DNA.
Talib J; Green C; Davis KJ; Urathamakul T; Beck JL; Aldrich-Wright JR; Ralph SF
Dalton Trans; 2008 Feb; (8):1018-26. PubMed ID: 18274682
[TBL] [Abstract][Full Text] [Related]
12. Reactions of cisplatin and cis-[PtI
Tolbatov I; Marzo T; Cirri D; Gabbiani C; Coletti C; Marrone A; Paciotti R; Messori L; Re N
J Inorg Biochem; 2020 Aug; 209():111096. PubMed ID: 32485478
[TBL] [Abstract][Full Text] [Related]
13. Insights into the molecular mechanisms of protein platination from a case study: the reaction of anticancer platinum(II) iminoethers with horse heart cytochrome c.
Casini A; Gabbiani C; Mastrobuoni G; Pellicani RZ; Intini FP; Arnesano F; Natile G; Moneti G; Francese S; Messori L
Biochemistry; 2007 Oct; 46(43):12220-30. PubMed ID: 17924668
[TBL] [Abstract][Full Text] [Related]
14. Mass Spectrometry Uncovers Molecular Reactivities of Coordination and Organometallic Gold(III) Drug Candidates in Competitive Experiments That Correlate with Their Biological Effects.
Meier SM; Gerner C; Keppler BK; Cinellu MA; Casini A
Inorg Chem; 2016 May; 55(9):4248-59. PubMed ID: 26866307
[TBL] [Abstract][Full Text] [Related]
15. Protein metalation by metal-based drugs: reactions of cytotoxic gold compounds with cytochrome c and lysozyme.
Gabbiani C; Massai L; Scaletti F; Michelucci E; Maiore L; Cinellu MA; Messori L
J Biol Inorg Chem; 2012 Dec; 17(8):1293-302. PubMed ID: 23132507
[TBL] [Abstract][Full Text] [Related]
16. Metallomic study on the metabolism of RAPTA-C and cisplatin in cell culture medium and its impact on cell accumulation.
Holtkamp HU; Movassaghi S; Morrow SJ; Kubanik M; Hartinger CG
Metallomics; 2018 Mar; 10(3):455-462. PubMed ID: 29484339
[TBL] [Abstract][Full Text] [Related]
17. Mixed copper-platinum complex formation could explain synergistic antiproliferative effect exhibited by binary mixtures of cisplatin and copper-1,10-phenanthroline compounds: An ESI-MS study.
Pivetta T; Lallai V; Valletta E; Trudu F; Isaia F; Perra D; Pinna E; Pani A
J Inorg Biochem; 2015 Oct; 151():107-14. PubMed ID: 26021964
[TBL] [Abstract][Full Text] [Related]
18. A mass spectrometric investigation of non-covalent interactions between ruthenium complexes and DNA.
Urathamakul T; Beck JL; Sheil MM; Aldrich-Wright JR; Ralph SF
Dalton Trans; 2004 Sep; (17):2683-90. PubMed ID: 15514752
[TBL] [Abstract][Full Text] [Related]
19. Protein-metallodrugs interactions: Effects on the overall protein structure and characterization of Au, Ru and Pt binding sites.
Loreto D; Ferraro G; Merlino A
Int J Biol Macromol; 2020 Nov; 163():970-976. PubMed ID: 32653380
[TBL] [Abstract][Full Text] [Related]
20. Molecular mass spectrometry in metallodrug development: a case of mapping transferrin-mediated transformations for a ruthenium(III) anticancer drug.
Jarosz M; Matczuk M; Pawlak K; Timerbaev AR
Anal Chim Acta; 2014 Dec; 851():72-7. PubMed ID: 25440667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
